Nanoparticle co-delivery of TGF-β and COX-2 siRNAs shows efficacy in vivo
Jan. 25, 2024
Researchers from Sirnaomics Inc. presented preclinical evaluation of novel intravenous polypeptide nanoparticle designed to simultaneously deliver two siRNAs, silencing TGF-β and COX-2.